Latest FUSN reports update at 2024-05-07: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Fusion Pharmaceuticals FUSN

$ 21.55 0.0%

Fusion Pharmaceuticals Balance Sheet 2011-2024 | FUSN

Annual Balance Sheet Fusion Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-22.5 M	-8.18 M	-46.2 M	-90.5 M	-65.3 M	-28.8 M	-	-	-	-	-	-	-
Long Term Debt	34.8 M	34.2 M	5.51 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	4.16 M	1.44 M	1.22 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	4.31 M	98.6 M	47.7 M	-	-	-	-	-	-	-
Total Current Liabilities	16.2 M	15.1 M	12.5 M	11.9 M	-	-	-	-	-	-	-	-	-
Total Liabilities	63.4 M	56.8 M	20.8 M	16.2 M	103 M	49.3 M	-	-	-	-	-	-	-
Deferred Revenue	333 K	333 K	1.54 M	1 M	-	-	-	-	-	-	-	-	-
Retained Earnings	-377 M	-282 M	-194 M	-113 M	-34.8 M	-18.6 M	-	-	-	-	-	-	-
Total Assets	286 M	219 M	252 M	311 M	69.4 M	31.4 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	61.5 M	43.9 M	52.9 M	90.5 M	67.1 M	-	-	-	-	-	-	-	-
Book Value	222 M	162 M	231 M	295 M	-33.5 M	-17.9 M	-	-	-	-	-	-	-
Total Shareholders Equity	222 M	162 M	231 M	295 M	-33.5 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Fusion Pharmaceuticals

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	49.7 M	34.8 M	34.6 M	34.5 M	34.8 M	34.2 M	34.1 M	9.63 M	5.56 M	5.51 M	5.78 M	6.08 M	6.32 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	82 M	63.4 M	64.9 M	65.3 M	65.7 M	56.8 M	55.4 M	29.2 M	20.5 M	20.8 M	21.8 M	18.6 M	18.2 M	16.2 M	16.2 M	16.2 M	16.2 M	10.3 M	10.3 M	10.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	333 K	333 K	333 K	333 K	333 K	333 K	412 K	707 K	1.1 M	1.54 M	2.29 M	1.73 M	1 M	1 M	1 M	1 M	1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-410 M	-377 M	-349 M	-331 M	-306 M	-282 M	-257 M	-233 M	-214 M	-194 M	-177 M	-158 M	-131 M	-113 M	-113 M	-113 M	-113 M	-34.8 M	-34.8 M	-34.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	324 M	286 M	253 M	268 M	267 M	219 M	238 M	228 M	236 M	252 M	268 M	282 M	297 M	311 M	311 M	311 M	311 M	69.4 M	69.4 M	69.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	27.8 M	61.5 M	26.8 M	32 M	54.9 M	43.9 M	107 M	63 M	60.7 M	52.9 M	40.3 M	29.5 M	41.1 M	92.4 M	90.5 M	90.5 M	90.5 M	65.3 M	65.3 M	65.3 M	-	29.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	242 M	222 M	188 M	203 M	201 M	162 M	183 M	199 M	215 M	231 M	246 M	264 M	279 M	295 M	295 M	295 M	295 M	59.1 M	59.1 M	59.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	242 M	222 M	188 M	203 M	201 M	162 M	183 M	199 M	215 M	231 M	246 M	264 M	279 M	295 M	295 M	295 M	295 M	-33.5 M	-33.5 M	-33.5 M	-21.7 M	-17.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency